This Month in The Journal  by Ratzel, Sarah & Cullinan, Sara B.
EDITORS’ CORNER
This Month in The Journal
Sarah Ratzel1 and Sara B. Cullinan2Enhancing Our Understanding of Breast Cancer
French et al., page 489
For some years now, the hunt for variants associated with
disease risk has centered around genome-wide association
studies (GWASs), but unsatisfyingly, many GWAS ‘‘hits’’
provide little information about the underlying biology
that contributes to the risk signal. As a part of a large, inter-
national consortium, French et al. now report that variants
at 11q13, a locus strongly associated with breast cancer
risk, map to enhancer elements that regulate cyclin D1
(CCND1) expression. Their follow-up analysis of a breast
cancer GWAS hit utilized a new genotyping chip, which
was customized to enable fine mapping of variants associ-
ated with breast, ovarian, and prostate cancers. The stron-
gest hits mapped to regulatory elements located upstream
of the CCND1 promoter, and follow-up experiments
showed—rather unexpectedly—that the risk allele is asso-
ciated with decreased levels of CCND1. Cyclin D1 is often
thought of as having oncogenic activity; however, as many
studies have shown, the activity of oncoproteins is often
more nuanced than what is depicted in traditional models.
Follow-up work will be necessary to address the long list of
questions that will emerge from this study, including
how the presence of other genetic variants influences the
activity of this risk allele, and to provide a more in-depth
characterization of the targets of these enhancer elements,
both in breast cancer and in a diverse range of other path-
ological conditions.Double-Edged Sword of Modern Hygiene
Raj et al., page 517
People today generally live in more hygienic environ-
ments as compared to the conditions present throughout
most of human evolution. Because the immune system
evolved under a constant barrage of pathogens that are
dissimilar to the hygienic conditions of the present day,
some investigators suspect that immune-related loci,
which were selected for owing to their importance in
protecting humans, might now be contributing factors
in immunity misregulation. This idea is known as the
hygiene hypothesis. In this issue, Raj et al. search for
evidence of positive selection in genome-wide association
data from ten different inflammatory diseases, including
Crohn disease, multiple sclerosis, systemic lupus erythe-1Scientific Editor, AJHG; 2Deputy Editor, AJHG
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The Ammatosus, and psoriasis. They found that many of these
disease-associated loci have been subject to positive selec-
tion, suggesting that, indeed, there has been an advan-
tage to maintaining these loci even though they might
now contribute to disease. Furthermore, positively
selected loci clustered into highly interconnected net-
works with shared cellular functions. Some of the loci
under selection also affected the expression of certain
RNAs, pointing to a mechanism for the effect of the
loci in disease pathogenesis. This integrated analysis pro-
vides a framework for evaluating how past pathogenic
challenges have potentially shaped modern immune
function and highlights some of the mechanisms that
might lead to inflammatory-disease susceptibility in indi-
viduals as they encounter pathogens and environmental
risks.Levering Genetic Information for Designing
Better Trials
Hu et al., page 547
Just about everyone agrees that preventing disease is
important—for both health-related and economic rea-
sons—and most people would argue that it would be
smart to use as much information as possible to aid pre-
vention efforts. It is for this reason that clinical trials
aimed at developing and/or assessing preventive therapies
try to enroll individuals who are most at risk of devel-
oping a particular disease. What is lacking, however, is
the integration into study design of one of the richest
kinds of data sets available to clinicians: genetic informa-
tion. In this issue, Hu et al. evaluate the benefits and
limitations of utilizing genetics-based risk predictions in
the design and implementation of clinical prevention
trials. Through a mixture of simulations and evaluation
of empirical data, they demonstrate that the integration
of genetic information can reduce the costs associated
with administering such trials, mainly through reductions
in the number of necessary participants and required
timeframes. Moreover, they suggest that the utilization
of data from existing biobanks could provide a wealth of
time- and money-saving opportunities. Although the
authors considered only trials aimed at evaluating preven-
tive therapies, given the amount of clinically actionable
genetic data that will become available in coming years,
we will no doubt see genetic information integrated intoy of Human Genetics. All rights reserved.
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the design and analysis phases of numerous types of
clinical trials.
Boning Up on WNT1
Pyott et al., page 590; Keupp et al., page 565
Osteogenesis imperfecta (OI) is a monogenic disorder
characterized primarily by bone fragility and low bone
mass. Affected individuals are susceptible to bone frac-
tures; for some, even simple bumps and bruises can lead
to broken bones. Although the genetic cause is known
for many forms of OI, especially those with dominant in-
heritance patterns, the underlying mutation is unknown
for several affected families. In this issue, Pyott et al. and
Keupp et al. provide evidence thatWNT1mutations cause
bone fragility; both groups find mutations in individuals
with recessively inherited OI, and Keupp et al. suggest
that heterozygous mutations can also cause osteoporosis.
Altered versions of WNT1 fail to activate canonical Wnt-
b-catenin signaling, a finding that is fitting with the
known role of the WNT1-interacting protein, LRP5, and
the TCF/LEF targets, SP7 and ALPL, in bone development.
Future experiments in human cells and with established
mouse models should reveal additional insights into how
disruption of this pathway causes human disease and
might also provide clues about new treatment options.476 The American Journal of Human Genetics 92, 475–476, April 4, 2Perrault Syndrome and Mitochondrial Protein
Homeostasis
Jenkinson et al., page 605; Pierce et al., page 614
The causes of premature ovarian failure and hearing loss
are numerous. Perrault syndrome is characterized by both
premature ovarian failure in females and hearing loss in
both males and females. Presumably because of genetic
heterogeneity, many cases of Perrault syndrome remain
genetically unresolved. Two studies in this issue identify
mutations in genes important for mitochondrial protein
homeostasis as causes of Perrault syndrome. Using both
homozygositymapping and exome sequencing, Jenkinson
et al. found mutations in mitochondrial CLPP, which en-
codes a protease with a crucial role in degrading mitochon-
drial proteins. Concurrently, Pierce et al. used exome
sequencing to identify mutations in the mitochondrial
leucyl-tRNA synthetase (LARS2) as a cause of Perrault syn-
drome. Because mutations that are important for both
translation and degradation of mitochondrial proteins
were identified, these results signal that defects in overall
protein homeostasis might underlie the pathogenesis of
Perrault syndrome. In light of these data, mutations in
other genes required for mitochondrial protein translation
or degradationmight be good candidates for further studies
in cases of genetically unresolved Perrault syndrome.013
